(50 days)
The Zeus Scientific, Inc. Rheumatoid Factor IgM ELISA test system is intended for the qualitative and semi-quantitative detection of RF IgM class antibody in human serum. The test system is intended for the manual or automated analysis of human serum for the presence of IgM RF. The test system is intended to be used as aid in the diagnosis of rheumatoid arthritis. The test is for in vitro diagnostic use.
Not Found
I am sorry, but the provided text does not contain information about the acceptance criteria, device performance, or any studies conducted to prove the device meets acceptance criteria. The document is an FDA 510(k) clearance letter for the "Aptus (Automated) Application for the RF Test System" (Rheumatoid Factor IgM ELISA Test System), indicating that it has been found substantially equivalent to a legally marketed predicate device.
The text does include the following:
- Device Name: Aptus (Automated) Application for the Rheumatoid Factor IgM ELISA Test System
- Indications for Use: The Zeus Scientific, Inc. Rheumatoid Factor IgM ELISA test system is intended for the qualitative and semi-quantitative detection of RF IgM class antibody in human serum. The test system is intended for the manual or automated analysis of human serum for the presence of IgM RF. The test system is intended to be used as aid in the diagnosis of rheumatoid arthritis. The test is for in vitro diagnostic use.
- Regulatory Class: II
- Product Code: DHR
- Application Date: September 28, 1998
- Received Date: September 29, 1998
- Clearance Date: November 18, 1998
To answer your specific questions, information regarding acceptance criteria, device performance, study details (sample sizes, provenance, ground truth, expert qualifications, adjudication methods, MRMC studies, standalone performance, training set details) would typically be found in the 510(k) summary or the full 510(k) submission, neither of which is present in the provided text.
{0}------------------------------------------------
Image /page/0/Picture/2 description: The image shows the seal of the Department of Health & Human Services USA. The seal is circular and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" around the perimeter. In the center of the seal is an emblem of an eagle with its wings spread.
NOV 1 8 1998
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Mr. Mark J. Kopnitsky Vice President of Research & Development Zeus Scientific, Inc. 200 Evans Way 08876 Branchburg, New Jersey
K983418 Re : Trade Name: Aptus (Automated) Application for the RF Test System Requlatory Class: II Product Code: DHR Dated: September 28, 1998 Received: September 29, 1998
Dear Mr. Kopnitsky:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such Existing major regulations affecting your device additional controls. can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Requlation (QS) for Medical Devices: General requlation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obliqation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
{1}------------------------------------------------
Page 2
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the requlation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Putman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Page 1 1 of of 1 1
510(k) Number (if known): _ K983418
Aptus (automated) Application for the Rheumatoid Factor Device Name: IgM ELISA Test System
Indications for Use:
The Zeus Scientific, Inc. Rheumatoid Factor IgM ELISA test system is intended for the qualitative and semi-quantitative detection of RF IgM class antibody in human serum. The test system is intended for the manual or automated analysis of human serum for the presence of IgM RF. The test system is intended to be used as aid in the diagnosis of rheumatoid arthritis. The test is for in vitro diagnostic use.
Revised: 11/06/98
Peter E. Makeri
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use /
OR
Over-The-Counter Use
(Per 21 CFR 801,109)
(Optional Format 1-
2-96)
§ 866.5775 Rheumatoid factor immunological test system.
(a)
Identification. A rheumatoid factor immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the rheumatoid factor (antibodies to immunoglobulins) in serum, other body fluids, and tissues. Measurement of rheumatoid factor may aid in the diagnosis of rheumatoid arthritis.(b)
Classification. Class II (performance standards).